We have also shown that dual G9a/DNMT1 blockade plays an antitumor and antimetastatic effect in NSCLC models and that the G9a/DNMT1-targteting drug CM-272 acts as a lung cancer drug sensitizer. Here, DNMT1 is linked to lung carcinoma.